Responding to an Arnold Ventures-backed opinion piece in the New England Journal of Medicine attacking tax-exempt hospitals and the 340B program, AHA General Counsel and Secretary Melinda Hatton says the authors’ disclosure form speaks volumes. “Specifically, that it is influenced by a shadowy organization with an obvious bias against hospitals. This article should be understood for what it is: just another attempt by a deep-pocketed organization with a biased agenda to attack hospitals.” READ MORE

Headline
The Centers for Medicare & Medicaid Services July 2 issued a proposed rule that would increase Medicare hospital outpatient prospective payment system…
Headline
Eli Lilly said June 1 it will deny 340B Drug Pricing Program discounts to providers that do not meet its documentation requirements by next week.In a statement…
Headline
The 4th U.S. Circuit Court of AppealsMay 28 agreed to rehear challenges to 340B contract pharmacy laws from West Virginia and Maryland. In April, a three-judge…
Headline
The Wall Street Journal today published a letter to the editor from AHA General Counsel Chad Golder responding to a May 7 editorial criticizing the 340B Drug…
Headline
The AHA today urged Eli Lilly to abandon its 340B Drug Pricing Program claims-data policy and work with the AHA to develop a functional third-party…
Headline
The AHA again is asking the Health Resources and Services Administration to take action after Eli Lilly warned hospitals that they could lose access to…